European regulator issues positive opinion on lung drug Daxas

04/26/2010 | Wall Street Journal, The

The European Medicines Agency backed Nycomed and Forest Laboratories' application to market lung drug Daxas as maintenance treatment for chronic bronchitis patients with severe chronic obstructive pulmonary disease. European approval would make Daxas the first oral drug in the region for the life-threatening condition.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA